1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
PAR-24-077: Health and Health Care Disparities Among Sexual and Gender Minority Populations of Minoritized Racial/Ethnic and Socio-Economic Statuses (R01 Clinical Trial Optional) is sponsored by National Institutes of Health (NIH). This Notice of Funding Opportunity (NOFO) supports innovative observational and intervention-based research to identify and characterize the pathways and mechanisms through which health and health care disparities occur among sexual and gender minority populations of minoritized…
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
NOT-DK-24-013: Notice of NIDDK Participation in PAR-24-077: "Addressing Health and Health Care Disparities among Sexual and Gender Minority Populations (R01 - Clinical Trials Optional)" Notice of NIDDK Participation in PAR-24-077: "Addressing Health and Health Care Disparities among Sexual and Gender Minority Populations (R01 - Clinical Trials Optional)" December 01, 2023- Addressing Health and Health Care Disparities among Sexual and Gender Minority Populations (R01 - Clinical Trials Optional).
See NOFO PAR-24-077 .
National Institute of Diabetes and Digestive and Kidney Diseases ( NIDDK ) The purpose of this notice is to inform potential applicants that the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) will participate, effective immediately, in PAR-24-077 , Addressing Health and Health Care Disparities among Sexual and Gender Minority Populations (R01 - Clinical Trials Optional)" National Institute on Minority Health and Health Disparities ( NIMHD ) National Institute on Alcohol Abuse and Alcoholism ( NIAAA ) National Institute on Drug Abuse ( NIDA ) National Institute of Mental Health ( NIMH ) National Center for Complementary and Integrative Health ( NCCIH ) National Cancer Institute ( NCI ) All applications to this funding opportunity announcement should fall within the mission of the Institutes/Centers.
The following NIH Offices may co-fund applications assigned to those Institutes/Centers. Office of Behavioral and Social Sciences Research ( OBSSR ) Sexual and Gender Minority Research Office ( SGMRO ) Assistance Listing Number(s): 93. 307, 93.
279, 93. 242, 93. 273, 93.
398 Modified to Read (in Bold) : Part 1.
Overview Information National Institute on Minority Health and Health Disparities ( NIMHD ) National Institute on Alcohol Abuse and Alcoholism ( NIAAA ) National Institute on Drug Abuse ( NIDA ) National Institute of Mental Health ( NIMH ) National Center for Complementary and Integrative Health ( NCCIH ) National Cancer Institute ( NCI ) National Institute of Diabetes and Digestive and Kidney Diseases ( NIDDK ) All applications to this funding opportunity announcement should fall within the mission of the Institutes/Centers.
The following NIH Offices may co-fund applications assigned to those Institutes/Centers. Office of Behavioral and Social Sciences Research ( OBSSR ) Sexual and Gender Minority Research Office ( SGMRO ) Modified to Read (in Bold): Assistance Listing Number(s): 93. 307, 93.
279, 93. 242, 93. 273, 93.
398, 93. 847 Modified to Read (in Bold): Part 2. Section I.
Notice of Funding Opportunity Description Specific Areas of Research Interest National Institute of Diabetes and Digestive and Kidney Diseases ( NIDDK ) NIDDK is interested in applications using an intersectionality perspective to address health and health care disparities in NIDDK-related diseases and conditions in sexual and gender minority populations who are from minoritized racial and ethnic populations and/or from lower SES, focused on innovative observational, etiological, and/or intervention-based research.
NIDDK mission diseases and conditions include diabetes and other endocrine and metabolic diseases; gastrointestinal, liver, and pancreatic diseases, nutritional disorders, and obesity; and kidney, urologic, and/or hematologic diseases.
NIDDK encourages research conducted using an equity lens, which considers—at each decision point—how processes, values, assumptions, and actions may affect inclusive excellence in our research and workforce and the overall well-being and health of diverse population groups.
NIDDK encourages applications that demonstrate consideration of the Tips for Pursuing Competent Health Equity Research (see Appendix G of Pathways to Health for All ).
This includes applications with interdisciplinary research teams comprised of individuals with a breadth of lived experiences and biomedical scientific expertise deemed necessary to positively inform the study design, research conduct, and applicability of research findings for the populations of interest.
Successful applicants will also leverage community-engaged research approaches that meaningfully include people who identify with SGM groups, minoritized racial/ethnic and socio-economic statuses, and/or who are living with NIDDK disease/conditions. To be assigned to the NIDDK, applications must be directly related to the mission of the NIDDK ( https://www. niddk.
nih. gov/about-niddk/meet-director/mission-vision ). NIDDK has many research areas within its mission, but all research related to relevant diseases may not be appropriate for NIDDK.
Applicants are strongly encouraged to contact NIDDK staff as soon as possible in the development of the application, so that NIDDK staff can help the applicant understand whether the proposed project is within the goals and mission of the Institute. Modified to Read (in Bold) : Part 2. Section VII.
Agency Contacts Scientific/Research Contact(s) NIDDK conducts and supports medical research in diabetes and other endocrine and metabolic diseases; gastrointestinal, liver, and pancreatic diseases, nutritional disorders, and obesity; and in kidney, urologic, and hematologic diseases. Visit NIDDK's Research Programs and Contacts page to identify a scientific/research contact. All other aspects of this NOFO remain the same.
Please direct all inquiries to: Bonnie Burgess-Beusse, Ph. D. Division of Digestive Diseases and Nutrition National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Weekly TOC for this Announcement NIH...
Turning Discovery Into Health ®
According to the current listing, eligibility includes: Proposals may be submitted by a wide range of institutions. Non-domestic (non-U. S.) Entities (Foreign Organizations) are not eligible to apply. Foreign components are not allowed. Confirm the full requirements in the official notice before applying.
PAR-24-077: Health and Health Care Disparities Among Sexual and Gender Minority Populations of Minoritized Racial/Ethnic and Socio-Economic Statuses (R01 Clinical Trial Optional) is funded by National Institutes of Health (NIH). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
PA-27-037 consolidates the Predoctoral to Postdoctoral Transition Award into a single parent announcement across 20 NIH components, with the next deadline December 8, 2026. The eligibility gate is not the science — it is a mandatory change of institution and mentor between the F99 and K00 phases.
Read articleA draft executive order would have put OMB Director Russell Vought on a commission with final say over NIH awards after peer review. Sen. Collins killed it by pointing at a provision Congress already passed. Here is what the episode teaches applicants about the December 11 cliff.
Read articlePA-27-034, PA-27-035 and PA-27-036 replace the institute-specific R25 announcements that research education programs have been built around for a decade. NCI, NIDA and NIGMS have already expired theirs early. Here is what the consolidation actually changes: an 8% indirect cost ceiling, a US-citizens-and-permanent-residents participant rule, a cooperative agreement variant that only exists on one of the three, and no clinical-trial-allowed companion anywhere.
Read article